- Additional Proxy Soliciting Materials - Non-Management (definitive) (DFAN14A)
16 Março 2009 - 6:13PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE
14A
(Rule 14a-101)
INFORMATION REQUIRED IN PROXY STATEMENT
SCHEDULE 14A INFORMATION
Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934
Filed by the Registrant
o
Filed by a Party other than the Registrant
þ
Check the appropriate box:
o
Preliminary Proxy Statement
o
Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
o
Definitive Proxy Statement
o
Definitive Additional Materials
þ
Soliciting Material Pursuant to §240.14a-12
(Name of Registrant as Specified In Its Charter)
Astellas Pharma Inc., Astellas US Holding, Inc.,
Sturgeon Acquisition, Inc.
(Names of Persons Filing Proxy Statement, if other than the Registrant)
Payment of Filing Fee (Check the appropriate box):
þ
|
|
No fee required.
|
|
o
|
|
Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
|
|
1)
|
|
Title of each class of securities to which transaction applies:
|
|
|
|
|
|
|
|
2)
|
|
Aggregate number of securities to which transaction applies:
|
|
|
|
|
|
|
|
3)
|
|
Per unit price or other underlying value of transaction computed pursuant to Exchange
Act Rule 0-11 (set
forth the amount on which the filing fee is calculated and state how it was determined):
|
|
|
|
|
|
|
|
4)
|
|
Proposed maximum aggregate value of transaction:
|
|
|
|
|
|
|
|
5)
|
|
Total fee paid:
|
|
|
|
|
|
o
|
|
Fee paid previously with preliminary materials.
|
|
o
|
|
Check box if any part of the fee is offset as provided by Exchange
Act Rule 0-11(a)(2) and identify the filing for which the
offsetting fee was paid previously. Identify the previous filing
by registration statement number, or the form or schedule and the
date of its filing:
|
|
1)
|
|
Amount Previously Paid:
|
|
|
|
|
|
|
|
2)
|
|
Form, Schedule or Registration Statement No:
|
|
|
|
|
|
|
|
3)
|
|
Filing Party:
|
|
|
|
|
|
|
|
4)
|
|
Date Filed:
|
|
|
|
|
|
The following press release was issued by Astellas Pharma Inc.
on Monday, March 16, 2009:
|
|
|
Media Contacts
|
|
Investor Contact
|
Sard Verbinnen & Co
|
|
Georgeson Inc.
|
Jim Barron (212) 687-8080
|
|
Tom Gardiner (212) 440-9872
|
Andrew Cole (415) 618-8750
|
|
|
ASTELLAS
TO TERMINATE OFFER FOR CV THERAPEUTICS
Tokyo, Japan, March 16, 2009
Astellas
Pharma Inc. (Astellas) today announced that it will
terminate its $16.00 per share offer for CV Therapeutics, Inc.
(Nasdaq: CVTX) and will not propose directors for the CV
Therapeutics Board of Directors or make any other proposals at
CV Therapeutics 2009 annual meeting. Astellas also intends
to withdraw a related lawsuit in the Delaware Chancery Court
against CV Therapeutics and its directors. Astellas is a
disciplined acquirer and does not see value for Astellas
stockholders in CV Therapeutics at the price level of the sale
announced on March 12.
About Astellas
Astellas Pharma Inc., with global headquarters in Tokyo and US
headquarters in Deerfield, Illinois, is a pharmaceutical company
dedicated to improving the health of people around the world
through the provision of innovative and reliable pharmaceutical
products. The organization is committed to becoming a global
pharmaceutical company by combining outstanding R&D and
marketing capabilities and continuing to grow in the world
pharmaceutical market.
Astellas was formed by the historical merger of Japans
third and fifth largest pharmaceutical
companies - Yamanouchi, founded in 1923, and Fujisawa,
founded in 1894. Today, Astellas is one of the largest
pharmaceutical companies in Japan with a market capitalization
of approximately $17.7 billion as of January 26, 2009,
and, for the fiscal year ended March 31, 2008, net income
of approximately $1.8 billion.
The company has approximately 14,000 employees worldwide.
This includes 7,500 in Japan, 3,300 in Europe, 2,200 in North
America and 1,000 in Asia. Some of Astellas core products
in the US are:
Lexiscan
®
(regadenoson) and
Adenoscan
®
(adenosine injection), pharmacologic stress agents indicated for
radionuclide myocardial perfusion imaging/scintigraphy
(MPI/S) in patients unable to undergo adequate exercise
stress;
Prograf
®
(tacrolimus), an immunosuppressant indicated for the prophylaxis
of organ rejection in patients receiving organ transplants; and
VESIcare
®
(solifenacin succinate), indicated for the treatment of
overactive bladder with symptoms of urgency, frequency, and urge
incontinence.
Astellas is publicly traded on the Tokyo Stock Exchange. For
more information about Astellas Pharma Inc., please visit
www.astellas.com
. For more information about Astellas
Pharma US, Inc., please visit
http://www.us.astellas.com/
.
###
CV Therapeutics (NASDAQ:CVTX)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
CV Therapeutics (NASDAQ:CVTX)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024